NIPPON-SHOKUBAI
29.2.2024 16:01:34 CET | Business Wire | Press release
NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter "Nippon Shokubai")(TOKYO:4114) combined forces with Trevi Systems Inc. (Headquarters: California, USA, CEO: John Webley, hereinafter “Trevi Systems” *1) in the development of the draw solution as a key component in the forward osmosis (hereinafter “FO”) system, which is a next generation system for seawater desalination and water treatment. With $4 million grant from US Department of Energy, Trevi Systems commenced a large scale project to demonstrate the production of fresh water at a volume of 500 m3 per day from seawater using the jointly developed draw solution on the islands of Hawaii in June, 2022 (*2) and completed the data collection in September, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216286680/en/
Figure 1 Comparison between RO system and FO system (Graphic: Business Wire)
In recent years, water shortage has become a serious problem in the world, and reverse osmosis (hereinafter “RO”) is widely used in the seawater desalination for agricultural and drinking water use and for treatment of industrial water. The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities. While this system enables the acquisition of high quality water, the large amount of electric power consumed by the pressurizing pump is considered an issue (Figure 1).
Meanwhile, the FO system is focused on as a means that will resolve this issue. The FO system utilizes the osmosis, which is a natural process and occurs when liquids of differing solute concentrations are separated by a semi-permeable membrane and water moves by the process of osmosis from the solution of lower concentration to that of higher concentration. In the seawater desalination, the FO system utilizes the difference in solute concentration in seawater and draw solution, and the natural osmotic pressure as a result of the draw solution on one side of a FO membrane (a semi-permeable membrane) to pull / transport fresh water from seawater into the draw solution with everything taking place under low pressure and energy conditions (Figure 1). Nippon Shokubai and Trevi Systems developed the draw solution to be separated from the recovered water using low grade thermal heat (Photo 1).
Trevi Systems is a company in the United States which was founded in 2010. Key elements of Trevi Systems’ FO system are the use of retrograde thermolytic solute draw solution and recycling of the draw solute back to the FO membrane (Figure 2). Trevi Systems conducted a pilot test to demonstrate the production of fresh water at a volume of 50 m3 per day from seawater in Middle East (the UAE) in 2016, which confirmed that the use of the FO system was able to reduce electric power consumption to about 1/3 compared to that of the RO system.
However, the improvement in the amount of water production is necessary for the widespread utilization of the FO system at full scale, and the improvement in the function of the draw solution as the key component is crucial for realizing this. Nippon Shokubai and Trevi Systems have successfully developed a draw solution with the capability of improving water production by 30% compared with the previous product. This developed draw solution was used in the demonstration pilot plant (500m3/day) operated by Trevi Systems on the islands of Hawaii (*2).
Key achievements of the project include:
- The fresh water recovery ratio from seawater exceeded 65% surpassing commercial RO systems’ capabilities.
- Electrical energy consumption is 1/3 compared with RO systems.
- Competitive Capital Costs: Demonstrated capital costs competitive with existing RO desalination systems.
Trevi Systems is committed to further expanding the NELHA plant’s capabilities, with plans to increase capacity to over 6,000m3/day at the same site, and showcasing the potential for zero liquid discharge (*3) by the use of brine and brine concentration for mineral recovery.
The FO system is under consideration to be introduced for seawater desalination in areas with high demand for water, such as the Middle East, as well as for brine concentration to achieve zero liquid discharge. Nippon Shokubai will make further efforts to improve the performance and functions of the draw solution with a view toward future expansion of the FO system.
*1: About Trevi Systems
Trevi Systems Inc. is California based company who is a pioneer in forward osmosis technology for sustainable and efficient water desalination and brine concentration. With a commitment to innovation and environmental responsibility, Trevi Systems continues to redefine the possibilities in utilizing forward osmosis and pressurized forward osmosis to deliver clean water and other resources from the most challenging wastewaters.
For more information: https://www.trevisystems.com/
*2: FO seawater desalination project in Hawaii
The FO system by Trevi Systems was adopted in the Sun Shot program by the Department of Energy, USA. An experiment will be conducted to demonstrate the desalination of seawater using the solar heat collection facility owned by the Natural Energy Laboratory of the Hawaii Authority (NELHA).
*3: zero liquid discharge (ZLD)
One of water treatment processes intended to reduce wastewater and produce clean water that is suitable for reuse. ZLD systems purify and recycle virtually all wastewater received.
The press release issued by Nippon Shokubai is here.
The press release issued by Trevi Systems is here.
About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers. We use chemistry to make the impossible possible, and offer unprecedented solutions to the world, specifically in Environment & Energy, Electronics & Imaging and Daily Use fields. Our corporate mission is "TechnoAmenity: Providing prosperity and comfort to people and society with our unique technology".
For more information: https://www.shokubai.co.jp/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216286680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
